Germany Pneumococcal Vaccines Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 425 Million |
| Market Size (2029) | USD 476.20 Million |
| CAGR (2024 - 2029) | 2.30 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Germany Pneumococcal Vaccines Market Analysis
The Germany Pneumococcal Vaccines Market size is estimated at USD 425 million in 2024, and is expected to reach USD 476.20 million by 2029, at a CAGR of 2.30% during the forecast period (2024-2029).
Pneumococcal vaccines protect children and adults from serious infections caused by pneumonia. There are two main types of pneumococcal vaccines: pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV). These vaccines contain different types of pneumococcus, which are combined to create doses for vaccinating children and adults. The increasing prevalence of pneumonia, increasing government awareness programs regarding pneumonia immunization, and growing research and development for developing novel vaccines are the major factors contributing to market growth.
The high prevalence of invasive pneumococcal disease (IPD) amongst the geriatric population in the country is projected to drive market growth during the forecast period. For instance, according to an article published in the Epidemiology & Infection Journal in July 2022, invasive pneumococcal disease (IPD) in people aged over 60 is rising in Germany. Thus, the high prevalence of IPD among the elderly population is projected to lead to an increased demand for pneumococcal vaccines by seeking vaccination as a preventive measure among healthcare providers and individuals, thereby boosting market growth in the country.
In addition, the rising geriatric population in the country is also projected to enhance market growth during the forecast period. For instance, according to the article published by the Statistisches Bundesamt (Destatis) in December 2022, the number of people aged 67 years or over in Germany is projected to increase by around 4 million in 2022 to 20.0 million by the end of 2030. Therefore, the surging geriatric population in the country is estimated to drive market growth during the forecast period owing to an increase in demand for pneumococcal vaccines.
Moreover, the increasing government initiatives regarding pneumonia immunization are projected to drive market growth during the forecast period. For instance, in January 2022, the Standing Vaccination Committee (STIKO) vaccination recommendations at the Robert Koch Institute were launched. The STIKO vaccination primary goal was to vaccinate children up to 24 months of age with the pneumococcal conjugate vaccine in Germany to reduce morbidity from invasive pneumococcal diseases (IPD) and resulting consequences such as hospitalization, disability, and death. Thus, the STIKO's recommendation to vaccinate all children up to 24 months of age with the pneumococcal conjugate vaccine is projected to boost vaccination rates among infants and toddlers in Germany significantly.
Therefore, factors such as the high prevalence of IPD amongst the geriatric population in the country and the active participation of government bodies, such as launching standard vaccination programs, are projected to drive market growth during the forecast period.
However, factors such as long duration and high cost of producing pneumococcal vaccines may hinder market growth during the study period.
Germany Pneumococcal Vaccines Market Trends
The Pneumococcal Polysaccharide Vaccine Segment is Expected to Show Significant Growth Over the Forecast Period
The Pneumococcal Polysaccharide Vaccine (PPSV) is mainly used to protect against infections caused by the bacterium Streptococcus pneumoniae, commonly known as pneumococcus. This vaccine contains fragments of the polysaccharide (sugar) capsules that surround the bacterium. These capsules help the bacterium evade the immune system, and the vaccine helps the body develop immunity against them.
The factors driving the PPSV segment growth include the advantages of PPSV over PCV, recommendations by healthcare authorities, regular reminders for booster shots in Germany, and the surging geriatric population. PPSV covers more pneumococcal serotypes (strains) than Pneumococcal conjugate vaccine (PCV). This makes it effective against a broader spectrum of pneumococcal infections. In addition, PPSV is typically administered as a single dose for adults, while PCV often requires multiple amounts for infants and young children. This single-dose convenience can make PPSV more practical for specific populations. Thus, such advantages offered by polysaccharide vaccines is expected to contribute to the segment growth during the forecast period.
Healthcare authorities' recommendations and regular booster shot reminders can increase public awareness about the importance of pneumococcal vaccination among adults, which is set to drive greater demand for PPSV. For instance, as per the report published by the Robert Koch Institute in January 2022, Pneumovax 23 (PPSV23) is recommended as a standard vaccination for people aged 60 years and above in Germany. As per the same source, individuals of 16 years of age or older should receive a vaccination with PPSV23, and as these vaccines provide only temporary protection, vaccination with PPSV23 should be repeated at intervals of at least six years. Thus, repeated vaccinations every six years ensure a continuous demand for PPSV23, especially among the targeted age group (16 or older) and individuals aged 60 and above. This ongoing need for booster shots will sustain market growth during the forecast period.
Germany, like many other developed countries, has an aging population. As more individuals reach the age of 60 and older, there will be a larger pool of eligible candidates for PPSV23 vaccination, contributing to market expansion. For instance, as per the data released by the Statistisches Bundesamt (Destatis) in March 2023, the number of geriatric people in need of long-term care in Germany is set to increase by 37% by the end of 2055. According to the same source, the senior population will likely to reach around 6.8 million by 2055. Thus, the surging aging population will drive the PPSV segment growth during the forecast period.
Therefore, factors such as various advantages associated with PPSV over PCV, recommendations by government bodies for PPSV as a standard vaccination, and surging geriatric population are projected to drive segment growth during the forecast period.
The Prevnar 13 Segment is Expected to Register the Significant Share of the Market Over the Forecast Period
Prevnar 13 is a pneumococcal conjugate vaccine designed to protect against 13 specific strains of the bacterium Streptococcus pneumoniae. It offers several advantages, including its ability to prevent infections such as pneumonia, bloodstream infections, and meningitis caused by these strains. Prevnar 13 is particularly effective in protecting infants, young children, and adults with certain risk factors, making it a valuable tool in reducing the burden of pneumococcal diseases.
The recommendation for sequential immunization with Prevenar 13 (PCV13) for individuals with specific risk factors for pneumococcal diseases, such as immune deficiencies and anatomical risk factors, is projected to drive the growth of the Prevenar 13 segment in Germany during the forecast period.
For instance, in January 2022, the Robert Koch Institute recommended the use of PCV13 for people with immune deficiencies like T-cell deficiency or defective T-cell function, deficiency or dysfunction of myeloid cells, neoplastic diseases like HIV infection, and people with anatomical and foreign-material associated risk factors like a cochlear implant. The government recommended sequential immunization with 13-valent conjugate PCV13 (Prevenar 13), followed by PPSV23 (Pneumovax).
Thus, the recommendation for sequential immunization broadens the eligible population for Prevenar 13 beyond the standard childhood vaccination age group. Individuals with risk factors, including those with immune deficiencies and anatomical risk factors, are now candidates for Prevenar 13, increasing the market's potential reach. Also, the sequential immunization approach requires regular booster shots or revaccination, especially for individuals with immune deficiencies, which is estimated to sustain demand for Prevenar 13 in Germany over the forecast period.
In addition, the PCV13 is mainly recommended for children under five years in Germany, and the rising fertility rate in Germany is anticipated to boost the segment growth during the forecast period. For instance, according to the data released by the Statistisches Bundesamt (Destatis) in March 2023, the current fertility rate in the German population in 2023 is around 1.612 births per woman, a 0.31% increase from 2022. Thus, the rising fertility rate in Germany, as indicated by the rise in births per woman, is expected to drive the growth of the Prevnar 13 vaccine segment in the country.
With more deliveries, there is an expanded pool of infants and young children who are typically the primary recipients of Prevnar 13 vaccination. As the population grows in this age group, there will be an increased demand for vaccinations to protect children against pneumococcal diseases. This sustained demand for Prevnar 13 among infants and young children due to a higher fertility rate is likely to contribute to the growth of the segment in Germany during the forecast period.
Therefore, factors such as the high recommendation of Prevnar 13 for children under five years and the increasing fertility rate in the country are projected to drive segment growth during the forecast period.
Germany Pneumococcal Vaccines Industry Overview
The Germany pneumococcal vaccines market is consolidated due to a few large companies dominating the majority of market share, including GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc, and CSL Ltd., among others. Key players are using their existing customer bases in the region to maintain high-quality standards and gain a large market share. These players are investing heavily in advanced products and infrastructure, allowing them to process and analyze a large number of samples efficiently.
Germany Pneumococcal Vaccines Market Leaders
-
GlaxoSmithKline plc
-
Pfizer Inc.
-
Merck & Co., Inc
-
CSL Ltd.
-
Sanofi
*Disclaimer: Major Players sorted in no particular order
Germany Pneumococcal Vaccines Market News
- March 2024: The European Commission (EC) granted Pfizer Inc. marketing authorization for its 20-valent pneumococcal conjugate vaccine. In the European Union, including Germany, the vaccine is branded as PREVENAR 20 and is designed to protect infants and children from pneumococcal disease.
- February 2022: Pfizer Inc. received the European Medicines Agency (EMA) approval for its 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European Union (EU) under the brand name APEXXNAR. The vaccine is approved for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
Germany Pneumococcal Vaccines Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Government Awareness Programs and Introduction of Novel Pneumococcal Vaccines
4.2.2 Rising Prevalence Of Pneumonia and Surging Targeted Population
4.3 Market Restraints
4.3.1 High Cost and Long Duration of the Production
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value-USD)
5.1 By Vaccine Type
5.1.1 Pneumococcal Conjugate Vaccine
5.1.2 Pneumococcal Polysaccharide Vaccine
5.2 By Product Type
5.2.1 Prevnar 13
5.2.2 Synflorix
5.2.3 Pneumovax23
5.3 By Distribution Channel
5.3.1 Distribution Partner Companies
5.3.2 Non-governmental Organizations
5.3.3 Government Authorities
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline plc
6.1.2 Pfizer Inc.
6.1.3 Merck & Co., Inc
6.1.4 CSL Ltd.
6.1.5 Sanofi
6.1.6 Johnson and Johnson
6.1.7 Novartis AG
6.1.8 Astellas Pharma Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Germany Pneumococcal Vaccines Industry Segmentation
As per the scope of the report, pneumococcal vaccines are immunizations designed to protect against infections caused by the bacterium Streptococcus pneumoniae. This bacterium can lead to serious illnesses, including pneumonia, meningitis, and bloodstream infections. The Germany pneumococcal vaccines market is segmented into vaccine type, product type, and distribution channel. By vaccine type, the market is segment into conjugate vaccine and polysaccharide vaccine. By product type, the market is segmented into Prevnar 13, Synflorix, and Pneumovax23. By distribution channel, the market is segmented into distribution partner companies, non-governmental organizations, and government authorities). The report offers the value (in USD) for the above segments.
| By Vaccine Type | |
| Pneumococcal Conjugate Vaccine | |
| Pneumococcal Polysaccharide Vaccine |
| By Product Type | |
| Prevnar 13 | |
| Synflorix | |
| Pneumovax23 |
| By Distribution Channel | |
| Distribution Partner Companies | |
| Non-governmental Organizations | |
| Government Authorities |
Germany Pneumococcal Vaccines Market Research FAQs
How big is the Germany Pneumococcal Vaccines Market?
The Germany Pneumococcal Vaccines Market size is expected to reach USD 425 million in 2024 and grow at a CAGR of 2.30% to reach USD 476.20 million by 2029.
What is the current Germany Pneumococcal Vaccines Market size?
In 2024, the Germany Pneumococcal Vaccines Market size is expected to reach USD 425 million.
Who are the key players in Germany Pneumococcal Vaccines Market?
GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc, CSL Ltd. and Sanofi are the major companies operating in the Germany Pneumococcal Vaccines Market.
What years does this Germany Pneumococcal Vaccines Market cover, and what was the market size in 2023?
In 2023, the Germany Pneumococcal Vaccines Market size was estimated at USD 415.23 million. The report covers the Germany Pneumococcal Vaccines Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Germany Pneumococcal Vaccines Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Germany Pneumococcal Vaccines Industry Report
Statistics for the 2024 Germany Pneumococcal Vaccines market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Germany Pneumococcal Vaccines analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
